Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, UK.
Br J Pharmacol. 2012 Apr;165(7):2191-202. doi: 10.1111/j.1476-5381.2011.01706.x.
Tryptamine increases blood pressure by vasoconstriction, but little is known about its actions on the mesentery, in particular the resistance arteries. Tryptamine interacts with trace amine-associated receptors (TAARs) and because of its structural similarity to 5-HT, it may also interact with 5-HT receptors. Our hypothesis is therefore that the rat mesenteric arterial bed will exhibit vasopressor and vasodepressor responses to tryptamine via both 5-HT and TAARs.
Tryptamine-evoked responses were assayed from pressure changes of the rat-isolated mesenteric vasculature perfused at constant flow rate in the absence and presence of adrenoceptor and 5-HT receptor antagonists.
Tryptamine caused dose-dependent vasoconstriction of the mesenteric arterial bed as increases in perfusion pressure. These were unaffected by the α(1) -adrenoceptor antagonist, prazosin, but were attenuated by the non-selective α-adrenoceptor antagonist, phentolamine. The 5-HT(2A) receptor antagonists, ketanserin and ritanserin, abolished the tryptamine-induced pressure increases to reveal vasodilator responses in mesenteric beds preconstricted with phenylephrine. These tryptamine-induced vasodilator responses were unaffected by the 5-HT(7) receptor antagonist, SB269970, but were eliminated by the NOS inhibitor, N(ω) -nitro-L-arginine methyl ester (L-NAME). Tyramine and β-phenylethylamine also caused vasodilatation in pre-constricted vasculature, which was also abolished by L-NAME.
Tryptamine causes vasoconstriction of the mesenteric vasculature via 5-HT(2A) receptors, which when inhibited exposed vasorelaxant effects in pre-constricted tissues. The vasodilatation was independent of 5-HT(2A) and 5-HT(7) receptors but like that for tyramine and β-phenylethylamine was due to NO release. Potency orders suggest TAAR involvement in the vasodilatation by these trace amines.
色胺通过血管收缩增加血压,但对肠系膜的作用知之甚少,特别是阻力动脉。色胺与痕量胺相关受体(TAARs)相互作用,由于其与 5-HT 的结构相似,它也可能与 5-HT 受体相互作用。因此,我们的假设是,大鼠肠系膜动脉床将通过 5-HT 和 TAARs 对色胺表现出升压和降压反应。
在恒定流量下灌注大鼠分离肠系膜血管时,从肠系膜血管的压力变化中测定色胺诱发的反应,在不存在和存在肾上腺素能受体和 5-HT 受体拮抗剂的情况下。
色胺引起肠系膜动脉床的剂量依赖性血管收缩,导致灌注压升高。这些变化不受 α(1)-肾上腺素能受体拮抗剂哌唑嗪的影响,但被非选择性 α-肾上腺素能受体拮抗剂酚妥拉明减弱。5-HT(2A)受体拮抗剂酮色林和利坦色林消除了色胺引起的压力升高,揭示了预先用苯肾上腺素预收缩的肠系膜床上的血管扩张反应。这些色胺诱导的血管扩张反应不受 5-HT(7)受体拮抗剂 SB269970 的影响,但被一氧化氮合酶抑制剂 N(ω)-硝基-L-精氨酸甲酯 (L-NAME) 消除。酪胺和β-苯乙胺也引起预先收缩的血管扩张,这种扩张也被 L-NAME 消除。
色胺通过 5-HT(2A)受体引起肠系膜血管收缩,当抑制这些受体时,在预先收缩的组织中暴露血管舒张作用。血管舒张与 5-HT(2A)和 5-HT(7)受体无关,但与酪胺和β-苯乙胺相似,是由于一氧化氮释放所致。效力顺序表明 TAAR 参与这些痕量胺的血管舒张作用。